Optimal delivery of minocycline to the brain: Implication for human studies of acute neuroprotection
- Susan C. Fagan(corresponding author),
- David J. Edwards,
- Cesar V. Borlongan,
- Lin Xu,
- Ankur Arora,
- Giora Feuerstein
- University of Georgia,
- Augusta University,
- VA Medical Center,
- Wayne State University,
- Merck,
Scholary Output:
Contribution to journal
Article
Peer-review
Open access
Sustainable Development Goals
SDG 3 Good Health and Well
Abstract
Minocycline is currently under development as a neuroprotective agent in many different brain diseases. In more than a dozen experimental investigations in various models of brain injury, high doses of minocycline have been administered intraperitoneally. This report details new concerns with this route of administration and makes a case for intravenous dosing in experimental animals, particularly for acute neuroprotection, to optimize delivery to the brain and facilitate translation to human studies.
Publication Information
Output type
Scholary Output:
Contribution to journal
Article
Peer-reviewOriginal language
English (US)Pages from-to (Number of pages)
Pages 248-251 (4 pages)Journal (Volume, Issue Number)
Experimental Neurology (Volume 186, Issue 2)Publication milestones
- Published - 04/2004
Publication status
Published - 04/2004
ISSN
0014-4886Publication IDs
- Scopus: 1542722933
- PubMed: 15026261
Publication metrics
Metrics
SciVal
FWCI
2.91
SciVal
Author count
7
SciVal
citations
107
SciVal
Paper percentile
94
SciVal
Top percentile
10
Fractional count
1
Fractional count
0.14
Fractional count
6
Fractional count
0.86
Fractional count
1
Fractional count
1
PlumX, opens in new tab
Mentions
1
Captures
64
Citation count
115
Funding Details
This work was supported by grants from NINDS (1U01NS43127-01 and RO1NS044216-01) and the American Heart Association Southeast Affiliate (SCF, CVB), VA Merit Review (DCH), and VA Career Development Award (CVB).